Anti-VEGF protein compositions and methods for producing the same

Patent metadata

Field	Value
Publication number	US-11299532-B2
Application number	US-202117489495-A
Country	US
Kind code	B2
Filing date	Sep 29, 2021
Priority date	Dec 6, 2019
Publication date	Apr 12, 2022
Grant date	Apr 12, 2022

Abstract

The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions in chemically defined media to reduce amounts of certain Aflibercept variants.

First claim

What is claimed is:

1. A method of producing aflibercept, comprising:
(a) binding aflibercept from a clarified harvest to a Protein A resin, wherein said aflibercept is expressed by cells cultured in a chemically defined medium (CDM), and wherein said aflibercept includes variants that have at least one oxidized amino acid residue selected from the group consisting of tryptophan, histidine, phenylalanine, tyrosine and a combination thereof;
(b) eluting said aflibercept of step (a) forming an affinity eluate, wherein said affinity eluate has a first color,
wherein said first color is no more yellow-brown than European Color Standard BY1;

(c) subjecting said affinity eluate comprising aflibercept to anion exchange chromatography (AEX) column; and
(d) collecting a flowthrough fraction, wherein said flowthrough fraction has a second color,
wherein said second color has a European Color Standard BY2 or greater, and
wherein said first color of said affinity eluate is a more intense yellow brown color than said second color of said flowthrough fraction when said affinity eluate and flowthrough fraction protein concentrations are normalized.

2. The method of claim 1 , wherein said cell is selected from the group consisting of CHO, NS0, Sp2/0, embryonic kidney cells and BHK.

3. The method of claim 1 , wherein said oxidized amino acid residue is histidine.

4. The method of claim 1 , wherein said oxidized amino acid residue is tryptophan.

5. The method of claim 1 , wherein said AEX column comprises an anionic exchange substituent including diethylaminoethyl (DEAE), quaternary aminoethyl (QAE) and quaternary amine (Q) groups.

6. The method of claim 1 , wherein said aflibercept variant is selected from an amino acid residue on a polypeptide having an amino acid sequence as set forth in the group consisting of: SEQ ID NO.: 17, SEQ ID NO.: 18, SEQ ID NO.: 19, SEQ ID NO.: 20, SEQ ID NO.: 21, SEQ ID NO.: 22, SEQ ID NO.: 23, SEQ ID NO.: 56, SEQ ID NO.: 69, SEQ ID NO.: 70, SEQ ID NO.: 71 and combinations thereof.

7. The method of claim 1 , further comprising after binding aflibercept from said clarified harvest, subjecting said aflibercept to one or more further chromatographic steps selected from the group consisting of: cation exchange chromatography, hydrophobic interactive chromatography, size exclusion chromatography and a combination thereof.

8. The method of claim 6 , wherein said aflibercept variant is selected from an amino acid residue on a polypeptide having an amino acid sequence comprising SEQ ID NO.: 17.

9. The method of claim 6 , wherein said aflibercept variant is selected from an amino acid residue on a polypeptide having an amino acid sequence comprising SEQ ID NO.: 18.

10. The method of claim 6 , wherein said aflibercept variant is selected from an amino acid residue on a polypeptide having an amino acid sequence comprising SEQ ID NO.: 19.

11. The method of claim 6 , wherein said aflibercept variant is selected from an amino acid residue on a polypeptide having an amino acid sequence comprising SEQ ID NO.: 20.

12. The method of claim 6 , wherein said aflibercept variant is selected from an amino acid residue on a polypeptide having an amino acid sequence comprising SEQ ID NO.: 21.

13. The method of claim 6 , wherein said aflibercept variant is selected from an amino acid residue on a polypeptide having an amino acid sequence comprising SEQ ID NO.: 22.

14. The method of claim 6 , wherein said aflibercept variant is selected from an amino acid residue on a polypeptide having an amino acid sequence comprising SEQ ID NO.: 23.

15. The method of claim 6 , wherein said aflibercept variant is selected from an amino acid residue on a polypeptide having an amino acid sequence comprising SEQ ID NO.: 56.

16. The method of claim 6 , wherein said aflibercept variant is selected from an amino acid residue on a polypeptide having an amino acid sequence comprising SEQ ID NO.: 69.

17. The method of claim 6 , wherein said aflibercept variant is selected from an amino acid residue on a polypeptide having an amino acid sequence comprising SEQ ID NO.: 70.

18. The method of claim 6 , wherein said aflibercept variant is selected from an amino acid residue on a polypeptide having an amino acid sequence comprising SEQ ID NO.: 71.

19. A method of producing aflibercept, comprising:
(a) binding aflibercept from a clarified harvest cultured (CDM) to a Protein A resin, wherein said aflibercept is expressed by cells cultured in a chemically defined medium (CDM), and wherein said aflibercept includes oxidized species of aflibercept that have at least one oxidized amino acid residue selected from the group consisting of tryptophan, histidine, phenylalanine, tyrosine and a combination thereof;
(b) eluting said aflibercept of step (a) forming an affinity eluate, wherein said affinity eluate comprises oxidized species of aflibercept;
(c) subjecting said eluted aflibercept to anion exchange (AEX) chromatography column; and
(d) collecting a flowthrough fraction, wherein the percent of oxidized species of aflibercept in said affinity eluate is greater than the percent of oxidized species of aflibercept in said flowthrough fraction when the concentrations of protein in said affinity eluate and flowthrough fraction are normalized,
wherein said oxidized species of aflibercept is measured by subjecting said affinity eluate and said flowthrough fractions to digestion, followed by their analysis using reverse-phase ultra-performance chromatography (UPLC), detection at wavelengths of 280 nm, 320 nm and 350 nm and mass spectrometry analysis using a first mobile phase of 0.1% v/v formic acid in water and a second mobile phase of 0.1% v/v formic acid in acetonitrile and
wherein the percent of oxidized species of aflibercept in said flowthrough fraction is reduced by at least about 10% compared to the percent of oxidized species of aflibercept in said affinity eluate.

20. The method of claim 19 , wherein said cell is selected from theft group consisting of CHO, NS0, Sp2/0, embryonic kidney cells and BHK.

21. The method of claim 19 , wherein said oxidized amino acid residue is histidine.

22. The method of claim 19 , wherein said oxidized amino acid residue is tryptophan.

Assignees

• Regeneron Pharma

Inventors

• Tustian Andrew
• Vartak Ankit
• Daly Thomas
• Pyles Erica
• Palackal Nisha
• Wang Shunhai
• Li Ning

Classifications

• C12N2529/10

  Stimulation by light · CPC title

• C12N15/85

  for animal cells · CPC title

• C07K1/06

  using protecting groups or activating agents {(C07K1/003, C07K1/006 take precedence)} · CPC title

• C12N2510/02

  Cells for production · CPC title

• C07K1/165

  mixed-mode chromatography · CPC title